免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

臨床試験

The P.A.U.S.E.® Spectacle Study

NCT: NCT06577948 · ACTIVE_NOT_RECRUITING

NCT識別子NCT06577948
ステータスACTIVE_NOT_RECRUITING
開始日2024-09-14
Sponsornthalmic Pty Ltd (NETWORK)
First posted
Last updated

概要

The goal of this clinical trial is to learn if spectacle lenses using Phase Alteration Utilising Sub Elements (P.A.U.S.E.®) technology works to slow down the rate of myopia progression in myopic children. The first stage of the trial compares P.A.U.S.E.® spectacle lenses to single vision spectacle lenses in myopic children and the second stage looks at the rate of myopia progression in children while wearing P.A.U.S.E.® spectacle lenses. The main questions to answer are: Do P.A.U.S.E.® spectacle lenses slow down the rate of axial length growth? Do P.A.U.S.E.® spectacle lenses slow down the rate of increase in myopic refractive error? Researchers will compare P.A.U.S.E.® spectacle lenses to a single vision spectacle lens for 12 months followed by assessing P.A.U.S.E.® spectacle lenses for slowing down myopia progression for another 12 months. Participants will be initially randomly allocated to wear either P.A.U.S.E.® spectacle lenses or single vision spectacle lenses and visit the clinic on five occasions over the first 12 months period. After completing the first 12 months, all participants will wear P.A.U.S.E.® spectacle lenses and visit the clinic on three occasions over the second 12 months period.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。

↑